A pre-treatment CT-based weighted radiomic approach combined with clinical characteristics to predict durable clinical benefits of immunotherapy in advanced lung cancer

OBJECTIVES: To develop a pre-treatment CT-based predictive model to anticipate inoperable lung cancer patients' progression-free survival (PFS) to immunotherapy. METHODS: This single-center retrospective study developed and cross-validated a radiomic model in 185 patients and tested it in 48 pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Zhenchen, Chen, Minjiang, Hu, Ge, Pan, Zhengsong, Han, Wei, Tan, Weixiong, Zhou, Zhen, Wang, Mengzhao, Mao, Li, Li, Xiuli, Sui, Xin, Song, Lan, Xu, Yan, Song, Wei, Yu, Yizhou, Jin, Zhengyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748402/
https://www.ncbi.nlm.nih.gov/pubmed/36515714
http://dx.doi.org/10.1007/s00330-022-09337-7
_version_ 1784849814851158016
author Zhu, Zhenchen
Chen, Minjiang
Hu, Ge
Pan, Zhengsong
Han, Wei
Tan, Weixiong
Zhou, Zhen
Wang, Mengzhao
Mao, Li
Li, Xiuli
Sui, Xin
Song, Lan
Xu, Yan
Song, Wei
Yu, Yizhou
Jin, Zhengyu
author_facet Zhu, Zhenchen
Chen, Minjiang
Hu, Ge
Pan, Zhengsong
Han, Wei
Tan, Weixiong
Zhou, Zhen
Wang, Mengzhao
Mao, Li
Li, Xiuli
Sui, Xin
Song, Lan
Xu, Yan
Song, Wei
Yu, Yizhou
Jin, Zhengyu
author_sort Zhu, Zhenchen
collection PubMed
description OBJECTIVES: To develop a pre-treatment CT-based predictive model to anticipate inoperable lung cancer patients' progression-free survival (PFS) to immunotherapy. METHODS: This single-center retrospective study developed and cross-validated a radiomic model in 185 patients and tested it in 48 patients. The binary endpoint is the durable clinical benefit (DCB, PFS ≥ 6 months) and non-DCB (NDCB, PFS < 6 months). Radiomic features were extracted from multiple intrapulmonary lesions and weighted by an attention-based multiple-instance learning model. Aggregated features were then selected through L2-regularized ridge regression. Five machine-learning classifiers were conducted to build predictive models using radiomic and clinical features alone and then together. Lastly, the predictive value of the model with the best performance was validated by Kaplan-Meier survival analysis. RESULTS: The predictive models based on the weighted radiomic approach showed superior performance across all classifiers (AUCs: 0.75–0.82) compared with the largest lesion approach (AUCs: 0.70–0.78) and the average sum approach (AUCs: 0.64–0.80). Among them, the logistic regression model yielded the most balanced performance (AUC = 0.87 [95%CI 0.84–0.89], 0.75 [0.68–0.82], 0.80 [0.68-0.92] in the training, validation, and test cohort respectively). The addition of five clinical characteristics significantly enhanced the performance of radiomic-only model (train: AUC 0.91 [0.89–0.93], p = .042; validation: AUC 0.86 [0.80–0.91], p = .011; test: AUC 0.86 [0.76–0.96], p = .026). Kaplan-Meier analysis of the radiomic-based predictive models showed a clear stratification between classifier-predicted DCB versus NDCB for PFS (HR = 2.40–2.95, p < 0.05). CONCLUSIONS: The adoption of weighted radiomic features from multiple intrapulmonary lesions has the potential to predict long-term PFS benefits for patients who are candidates for PD-1/PD-L1 immunotherapies. KEY POINTS: • Weighted radiomic-based model derived from multiple intrapulmonary lesions on pre-treatment CT images has the potential to predict durable clinical benefits of immunotherapy in lung cancer. • Early line immunotherapy is associated with longer progression-free survival in advanced lung cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00330-022-09337-7.
format Online
Article
Text
id pubmed-9748402
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-97484022022-12-14 A pre-treatment CT-based weighted radiomic approach combined with clinical characteristics to predict durable clinical benefits of immunotherapy in advanced lung cancer Zhu, Zhenchen Chen, Minjiang Hu, Ge Pan, Zhengsong Han, Wei Tan, Weixiong Zhou, Zhen Wang, Mengzhao Mao, Li Li, Xiuli Sui, Xin Song, Lan Xu, Yan Song, Wei Yu, Yizhou Jin, Zhengyu Eur Radiol Chest OBJECTIVES: To develop a pre-treatment CT-based predictive model to anticipate inoperable lung cancer patients' progression-free survival (PFS) to immunotherapy. METHODS: This single-center retrospective study developed and cross-validated a radiomic model in 185 patients and tested it in 48 patients. The binary endpoint is the durable clinical benefit (DCB, PFS ≥ 6 months) and non-DCB (NDCB, PFS < 6 months). Radiomic features were extracted from multiple intrapulmonary lesions and weighted by an attention-based multiple-instance learning model. Aggregated features were then selected through L2-regularized ridge regression. Five machine-learning classifiers were conducted to build predictive models using radiomic and clinical features alone and then together. Lastly, the predictive value of the model with the best performance was validated by Kaplan-Meier survival analysis. RESULTS: The predictive models based on the weighted radiomic approach showed superior performance across all classifiers (AUCs: 0.75–0.82) compared with the largest lesion approach (AUCs: 0.70–0.78) and the average sum approach (AUCs: 0.64–0.80). Among them, the logistic regression model yielded the most balanced performance (AUC = 0.87 [95%CI 0.84–0.89], 0.75 [0.68–0.82], 0.80 [0.68-0.92] in the training, validation, and test cohort respectively). The addition of five clinical characteristics significantly enhanced the performance of radiomic-only model (train: AUC 0.91 [0.89–0.93], p = .042; validation: AUC 0.86 [0.80–0.91], p = .011; test: AUC 0.86 [0.76–0.96], p = .026). Kaplan-Meier analysis of the radiomic-based predictive models showed a clear stratification between classifier-predicted DCB versus NDCB for PFS (HR = 2.40–2.95, p < 0.05). CONCLUSIONS: The adoption of weighted radiomic features from multiple intrapulmonary lesions has the potential to predict long-term PFS benefits for patients who are candidates for PD-1/PD-L1 immunotherapies. KEY POINTS: • Weighted radiomic-based model derived from multiple intrapulmonary lesions on pre-treatment CT images has the potential to predict durable clinical benefits of immunotherapy in lung cancer. • Early line immunotherapy is associated with longer progression-free survival in advanced lung cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00330-022-09337-7. Springer Berlin Heidelberg 2022-12-14 2023 /pmc/articles/PMC9748402/ /pubmed/36515714 http://dx.doi.org/10.1007/s00330-022-09337-7 Text en © The Author(s), under exclusive licence to European Society of Radiology 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Chest
Zhu, Zhenchen
Chen, Minjiang
Hu, Ge
Pan, Zhengsong
Han, Wei
Tan, Weixiong
Zhou, Zhen
Wang, Mengzhao
Mao, Li
Li, Xiuli
Sui, Xin
Song, Lan
Xu, Yan
Song, Wei
Yu, Yizhou
Jin, Zhengyu
A pre-treatment CT-based weighted radiomic approach combined with clinical characteristics to predict durable clinical benefits of immunotherapy in advanced lung cancer
title A pre-treatment CT-based weighted radiomic approach combined with clinical characteristics to predict durable clinical benefits of immunotherapy in advanced lung cancer
title_full A pre-treatment CT-based weighted radiomic approach combined with clinical characteristics to predict durable clinical benefits of immunotherapy in advanced lung cancer
title_fullStr A pre-treatment CT-based weighted radiomic approach combined with clinical characteristics to predict durable clinical benefits of immunotherapy in advanced lung cancer
title_full_unstemmed A pre-treatment CT-based weighted radiomic approach combined with clinical characteristics to predict durable clinical benefits of immunotherapy in advanced lung cancer
title_short A pre-treatment CT-based weighted radiomic approach combined with clinical characteristics to predict durable clinical benefits of immunotherapy in advanced lung cancer
title_sort pre-treatment ct-based weighted radiomic approach combined with clinical characteristics to predict durable clinical benefits of immunotherapy in advanced lung cancer
topic Chest
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748402/
https://www.ncbi.nlm.nih.gov/pubmed/36515714
http://dx.doi.org/10.1007/s00330-022-09337-7
work_keys_str_mv AT zhuzhenchen apretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT chenminjiang apretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT huge apretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT panzhengsong apretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT hanwei apretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT tanweixiong apretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT zhouzhen apretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT wangmengzhao apretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT maoli apretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT lixiuli apretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT suixin apretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT songlan apretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT xuyan apretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT songwei apretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT yuyizhou apretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT jinzhengyu apretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT zhuzhenchen pretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT chenminjiang pretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT huge pretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT panzhengsong pretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT hanwei pretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT tanweixiong pretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT zhouzhen pretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT wangmengzhao pretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT maoli pretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT lixiuli pretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT suixin pretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT songlan pretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT xuyan pretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT songwei pretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT yuyizhou pretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer
AT jinzhengyu pretreatmentctbasedweightedradiomicapproachcombinedwithclinicalcharacteristicstopredictdurableclinicalbenefitsofimmunotherapyinadvancedlungcancer